TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP

Table 1 DLBCL patients’ characteristics and correlations with TP53 SNP rs1042522

Clinical parameters	No.	Genotype		P	Clinical parameters	No.	Genotype		P
Clinical parameters	No.	GG + GC	CC	P	Clinical parameters	No.	GG + GC	CC	P
Gender					β₂-MG
Male	175	147	28	0.213	Positive	109	79	30	0.004
Female	250	198	52	0.213	Negative	277	236	41	0.004
Age					LDH
≤60	269	216	53	0.543	Positive	192	155	37	0.83
>60	156	129	27	0.543	Negative	233	190	43	0.83
Stage					ESR
I-II	182	146	36	0.662	Positive	230	185	45	0.501
III-IV	243	199	44	0.662	Negative	143	119	24	0.501
IPI score					ECOG score
0–2	289	231	58	0.338	0–2	368	296	72	0.32
3–5	136	114	22	0.338	3–4	57	49	8	0.32
Subtype					HBV infection
GCB	112	92	20	0.709	Positive	200	159	41	0.355
Non-GCB	251	202	49	0.709	Negative	218	181	37	0.355
B symptoms					Treatment
Positive	234	200	34	0.012	CHOP/CHOP-like	136	107	29
Negative	191	145	46	0.012	R-CHOP	289	238	51	0.366

IPI International prognostic index, GCB Gernminal center B cell subtype, MG Microglobulin, LDH Lactate dehydrogenase, ESR Erythrocyte sedimentation rate, ECOG Eastern cooperative oncology group, HBV Hepatitis B virus

ISSN: 1471-2407